
CAS 1103522-45-7
:Aprocitentan
- Act-132577
Despropyl Macitentan (N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]sulfamide)
CAS:Compounds containing a pyrimidine ring, whether or not hydrogenated, or piperazine ring in the structure, nesoiFormel:C16H14Br2N6O4SFarbe und Form:Off-White SolidMolekulargewicht:543.9164Ref: IN-DA008TD9
1gNachfragen1mg157,00€5mg161,00€10mg191,00€25mg240,00€50mg602,00€100mgNachfragen250mgNachfragenN-Despropyl Macitentan (Aprocitentan)
CAS:Formel:C16H14Br2N6O4SFarbe und Form:White To Off-White SolidMolekulargewicht:546.20Aprocitentan
CAS:Aprocitentan (ACT-132577) is ETA and ETB antagonist .Formel:C16H14Br2N6O4SReinheit:99.17%Farbe und Form:SolidMolekulargewicht:546.19Ref: TM-T7817
1mg58,00€5mg116,00€10mg170,00€25mg311,00€50mg439,00€100mg655,00€200mg887,00€1mL*10mM (DMSO)142,00€N-Despropyl-macitentan
CAS:Kontrolliertes ProduktApplications N-Despropyl-macitentan, is an active metabolite which is part of a family of endothelin receptor antagonist that allows for treatment of pulmonary arterial hypertension (PAH)
References Atsmon, J., et al.: Clin. Pharmacokinet., 525, 685 (2013); Sidharta, P.N., et al.: Clin. Drug Invest. (2014)Formel:C16H14Br2N6O4SFarbe und Form:NeatMolekulargewicht:546.19Aprocitentan
CAS:Apcitentan is a vasoactive drug that belongs to the group of endothelin receptor antagonists. It is used in the treatment of erectile dysfunction and pulmonary hypertension. Apcitentan inhibits the angiotensin system, which includes angiotensin-converting enzyme (ACE), angiotensin II type 1 receptor (AT1R) and angiotensin II type 2 receptor (AT2R). This inhibition increases the levels of endothelin and dopamine β-hydroxylase, thereby decreasing blood pressure. Apcitentan has been shown to increase glomerular filtration rate and reduce proteinuria in patients with chronic kidney disease. In vivo studies have shown that apcitentan is rapidly absorbed from the gastrointestinal tract, reaching peak concentrations within one hour. The pharmacodynamics of apcitentan are characterized by an inhibitory effect on pde5. Pharmacokinetic studies have found that apcitentan is metabolized by CYP
Formel:C16H14Br2N6O4SReinheit:Min. 95%Molekulargewicht:546.19 g/mol









